{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:09:09Z","timestamp":1791544149885,"version":"4.3.4"},"reference-count":231,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1378\/chest.11-2291","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T02:39:00Z","timestamp":1328582340000},"page":"e24S-e43S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":932,"special_numbering":"S","title":["Parenteral Anticoagulants"],"prefix":"10.1016","volume":"141","author":[{"given":"David A.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor P.","family":"Baglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer Michel","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.11-2291_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"Am J Physiol"},{"key":"10.1378\/chest.11-2291_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/ajplegacy.1939.125.4.683","article-title":"The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin","volume":"125","author":"Brinkhous","year":"1939","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365516809076981","article-title":"Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis","volume":"21","author":"Abildgaard","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"issue":"7","key":"10.1378\/chest.11-2291_bib4","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1073\/pnas.76.7.3198","article-title":"Structure of the antithrombin-binding site in heparin","volume":"76","author":"Lindahl","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1378\/chest.11-2291_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"issue":"3","key":"10.1378\/chest.11-2291_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1073\/pnas.76.3.1218","article-title":"Correlation between structure and function of heparin","volume":"76","author":"Rosenberg","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6 suppl","key":"10.1378\/chest.11-2291_bib7","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1378\/chest.11-2291_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0049-3848(76)90105-5","article-title":"Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration","volume":"9","author":"Andersson","year":"1976","journal-title":"Thromb Res"},{"issue":"suppl","key":"10.1378\/chest.11-2291_bib9","first-page":"12","article-title":"Pharmacology of low molecular weight heparins","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1378\/chest.11-2291_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0038-1648001","article-title":"Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection","volume":"35","author":"Johnson","year":"1976","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2291_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1378\/chest.11-2291_bib12","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0021-9258(18)34900-7","article-title":"Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma","volume":"257","author":"Tollefsen","year":"1982","journal-title":"J Biol Chem"},{"issue":"9162","key":"10.1378\/chest.11-2291_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(98)09233-2","article-title":"New antithrombotic agents","volume":"353","author":"Hirsh","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1378\/chest.11-2291_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj1970599","article-title":"The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies","volume":"197","author":"Casu","year":"1981","journal-title":"Biochem J"},{"issue":"3","key":"10.1378\/chest.11-2291_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj2180725","article-title":"Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4","volume":"218","author":"Lane","year":"1984","journal-title":"Biochem J"},{"issue":"20","key":"10.1378\/chest.11-2291_bib16","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1016\/S0021-9258(18)90755-6","article-title":"Extension and structural variability of the antithrombin-binding sequence in heparin","volume":"259","author":"Lindahl","year":"1984","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1378\/chest.11-2291_bib17","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1016\/S0021-9258(17)43920-2","article-title":"A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin","volume":"258","author":"Nesheim","year":"1983","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1378\/chest.11-2291_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.78.2.829","article-title":"Multiple functional domains of the heparin molecule","volume":"78","author":"Oosta","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1378\/chest.11-2291_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0038-1646990","article-title":"The mode of action of heparin in plasma","volume":"60","author":"B\u00e9guin","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.11-2291_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1749-6632.1989.tb22507.x","article-title":"Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits","volume":"556","author":"Blajchman","year":"1989","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1378\/chest.11-2291_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1042\/bj2430579","article-title":"The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin","volume":"243","author":"Ofosu","year":"1987","journal-title":"Biochem J"},{"issue":"3","key":"10.1378\/chest.11-2291_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1971.tb01976.x","article-title":"Inhibition of thrombin induced aggregation of human platelets by heparin","volume":"8","author":"Eika","year":"1971","journal-title":"Scand J Haematol"},{"issue":"4","key":"10.1378\/chest.11-2291_bib23","first-page":"259","article-title":"Bleeding associated with antithrombotic therapy","volume":"17","author":"Kelton","year":"1980","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1172\/JCI109661","article-title":"Effect of heparin and heparin fractions on platelet aggregation","volume":"65","author":"Salzman","year":"1980","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1378\/chest.11-2291_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2141.1977.tb00666.x","article-title":"Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release","volume":"36","author":"Heiden","year":"1977","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1378\/chest.11-2291_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0049-3848(86)90094-0","article-title":"Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect","volume":"43","author":"Fernandez","year":"1986","journal-title":"Thromb Res"},{"issue":"27","key":"10.1378\/chest.11-2291_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis","volume":"307","author":"Hull","year":"1982","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1378\/chest.11-2291_bib28","doi-asserted-by":"crossref","first-page":"11256","DOI":"10.1016\/S0021-9258(18)33750-5","article-title":"Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase","volume":"257","author":"Castellot","year":"1982","journal-title":"J Biol Chem"},{"issue":"5595","key":"10.1378\/chest.11-2291_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/265625a0","article-title":"Suppression by heparin of smooth muscle cell proliferation in injured arteries","volume":"265","author":"Clowes","year":"1977","journal-title":"Nature"},{"issue":"3","key":"10.1378\/chest.11-2291_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0037-1615222","article-title":"The effects of standard and low molecular weight heparin on bone nodule formation in vitro","volume":"80","author":"Bhandari","year":"1998","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib31","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V86.4.1368.bloodjournal8641368","article-title":"The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria","volume":"86","author":"Shaughnessy","year":"1995","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1378\/chest.11-2291_bib32","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"issue":"suppl","key":"10.1378\/chest.11-2291_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3928\/0147-7447-19950702-08","article-title":"Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium","volume":"18","author":"Berkowitz","year":"1995","journal-title":"Orthopedics"},{"issue":"2","key":"10.1378\/chest.11-2291_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0038-1647289","article-title":"Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis\u2014a randomized clinical trial","volume":"64","author":"Pini","year":"1990","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1378\/chest.11-2291_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism","volume":"296","author":"Kearon","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1378\/chest.11-2291_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0049-3848(85)90244-0","article-title":"Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration","volume":"39","author":"Bara","year":"1985","journal-title":"Thromb Res"},{"issue":"4","key":"10.1378\/chest.11-2291_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archinte.1989.00390040013003","article-title":"A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip","volume":"149","author":"Powers","year":"1989","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1378\/chest.11-2291_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.53.4.691","article-title":"Heparin kinetics in venous thrombosis and pulmonary embolism","volume":"53","author":"Hirsh","year":"1976","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.11-2291_bib39","first-page":"379","article-title":"Antiphospholipid antibodies and ischemic stroke","volume":"1","author":"Brey","year":"1992","journal-title":"Heart Dis Stroke"},{"issue":"2","key":"10.1378\/chest.11-2291_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0167-4889(85)90177-6","article-title":"Binding and endocytosis of heparin by human endothelial cells in culture","volume":"845","author":"B\u00e2rzu","year":"1985","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1378\/chest.11-2291_bib41","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1172\/JCI115198","article-title":"Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo","volume":"87","author":"Sobel","year":"1991","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1378\/chest.11-2291_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/clpt.1982.16","article-title":"Heparin kinetics determined by three assay methods","volume":"31","author":"Bjornsson","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1378\/chest.11-2291_bib43","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.V60.6.1251.1251","article-title":"Kinetics of intravenously administered heparin in normal humans","volume":"60","author":"de Swart","year":"1982","journal-title":"Blood"},{"key":"10.1378\/chest.11-2291_bib44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0954-6820.1963.tb17446.x","article-title":"The elimination from plasma of intravenous heparin. An experimental study on dogs and humans","volume":"173","author":"Olsson","year":"1963","journal-title":"Acta Med Scand"},{"issue":"1","key":"10.1378\/chest.11-2291_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0049-3848(78)90087-7","article-title":"Vascular sequestration of heparin","volume":"12","author":"Mahadoo","year":"1978","journal-title":"Thromb Res"},{"issue":"3","key":"10.1378\/chest.11-2291_bib46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1042\/bj1390699","article-title":"Studies on the heparin sulphamidase activity from rat spleen. Intracellular distribution and characterization of the enzyme","volume":"139","author":"Friedman","year":"1974","journal-title":"Biochem J"},{"issue":"6","key":"10.1378\/chest.11-2291_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0049-3848(79)90004-5","article-title":"Catabolism of low-dose heparin in man","volume":"14","author":"Dawes","year":"1979","journal-title":"Thromb Res"},{"issue":"5059","key":"10.1378\/chest.11-2291_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/212293a0","article-title":"Heparin metabolism: isolation and characterization of uroheparin","volume":"212","author":"McAllister","year":"1966","journal-title":"Nature"},{"issue":"9","key":"10.1378\/chest.11-2291_bib49","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib50","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1378\/chest.09-0959","article-title":"Early anticoagulation is associated with reduced mortality for acute pulmonary embolism","volume":"137","author":"Smith","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1378\/chest.11-2291_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archinte.1991.00400020085018","article-title":"A standard heparin nomogram for the management of heparin therapy","volume":"151","author":"Cruickshank","year":"1991","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1378\/chest.11-2291_bib52","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.164.10.1077","article-title":"Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism","volume":"164","author":"Prandoni","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1378\/chest.11-2291_bib53","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","article-title":"ACC\/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1378\/chest.11-2291_bib54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(99)00351-4","article-title":"1999 update: ACC\/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"34","author":"Ryan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.11-2291_bib55","series-title":"Heparin: Chemical and Biological Properties, Clinical Applications","first-page":"517","article-title":"Heparin-induced bleeding","author":"Levine","year":"1989"},{"issue":"8492","key":"10.1378\/chest.11-2291_bib56","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(86)91421-2","article-title":"Heparin doses and major bleedings","volume":"1","author":"Morabia","year":"1986","journal-title":"Lancet"},{"issue":"4","key":"10.1378\/chest.11-2291_bib57","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"10.1378\/chest.11-2291_bib58","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"issue":"4","key":"10.1378\/chest.11-2291_bib59","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators","volume":"90","author":"GUSTO IIA Investigators","year":"1994","journal-title":"Circulation"},{"issue":"11","key":"10.1378\/chest.11-2291_bib60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators","volume":"335","author":"GUSTO IIB Investigators","year":"1996","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1378\/chest.11-2291_bib61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1378\/chest.11-2291_bib62","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1378\/chest.11-2291_bib63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0002-9343(87)90004-0","article-title":"Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy","volume":"82","author":"Landefeld","year":"1987","journal-title":"Am J Med"},{"issue":"5","key":"10.1378\/chest.11-2291_bib64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0002-9343(90)90174-C","article-title":"A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy","volume":"89","author":"Landefeld","year":"1990","journal-title":"Am J Med"},{"issue":"15","key":"10.1378\/chest.11-2291_bib65","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/archinte.1996.00440140067006","article-title":"The effectiveness of implementing the weight-based heparin nomogram as a practice guideline","volume":"156","author":"Raschke","year":"1996","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1378\/chest.11-2291_bib66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.11-2291_bib67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ajcp\/74.5.668","article-title":"Heparin and the activated partial thromboplastin time\u2014a difference between the in-vitro and in-vivo effects and implications for the therapeutic range","volume":"74","author":"Bain","year":"1980","journal-title":"Am J Clin Pathol"},{"issue":"21","key":"10.1378\/chest.11-2291_bib68","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1001\/archinte.1997.00440420107010","article-title":"Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays","volume":"157","author":"Baker","year":"1997","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1378\/chest.11-2291_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archinte.161.3.385","article-title":"Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin","volume":"161","author":"Bates","year":"2001","journal-title":"Arch Intern Med"},{"issue":"4 suppl","key":"10.1378\/chest.11-2291_bib70","first-page":"530","article-title":"Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time","volume":"76","author":"Brandt","year":"1981","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1378\/chest.11-2291_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jcp.49.1.10","article-title":"Wide variability in the sensitivity of aPTT reagents for monitoring of heparin dosage","volume":"49","author":"Kitchen","year":"1996","journal-title":"J Clin Pathol"},{"issue":"9","key":"10.1378\/chest.11-2291_bib73","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1378\/chest.11-2291_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajcp\/110.2.173","article-title":"Comparing different lots of activated partial thromboplastin time reagent: analysis of two methods","volume":"110","author":"Rosborough","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ajcp\/89.1.19","article-title":"The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer","volume":"89","author":"Shojania","year":"1988","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1378\/chest.11-2291_bib76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ajcp\/93.5.684","article-title":"Comparison of two aPTT methods of monitoring heparin therapy. aPTT ratio and heparin response of pooled normal plasma","volume":"93","author":"Zanke","year":"1990","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1378\/chest.11-2291_bib77","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1592\/phco.19.11.922.31573","article-title":"Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration","volume":"19","author":"Koerber","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1378\/chest.11-2291_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1515\/CCLM.1998.168","article-title":"Evaluation of the activated partial thromboplastin time (aPTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring","volume":"36","author":"Manzato","year":"1998","journal-title":"Clin Chem Lab Med"},{"issue":"5 pt 2","key":"10.1378\/chest.11-2291_bib79","first-page":"804","article-title":"Apparent heparin resistance from elevated factor VIII during pregnancy","volume":"96","author":"Raschke","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1378\/chest.11-2291_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ajcp\/108.6.662","article-title":"Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients","volume":"108","author":"Rosborough","year":"1997","journal-title":"Am J Clin Pathol"},{"issue":"19","key":"10.1378\/chest.11-2291_bib81","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/ajhp\/55.19.2002","article-title":"Establishing an institution-specific therapeutic range for heparin","volume":"55","author":"Volles","year":"1998","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1378\/chest.11-2291_bib82","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0749-0704(18)30295-1","article-title":"Toxic effects of drugs used in the ICU. Anticoagulants and thrombolytics. Risks and benefits [review]","volume":"7","author":"Guidry","year":"1991","journal-title":"Crit Care Clin"},{"issue":"1","key":"10.1378\/chest.11-2291_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-0038-1645678","article-title":"Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples","volume":"63","author":"van den Besselaar","year":"1990","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib84","first-page":"837","article-title":"Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys","volume":"104","author":"Cuker","year":"2010","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2291_bib85","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1538-7836.2008.03224.x","article-title":"Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time","volume":"7","author":"Cuker","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1378\/chest.11-2291_bib86","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archinte.1997.00440280157015","article-title":"Management of iliofemoral thrombosis in a pregnant patient with heparin resistance","volume":"157","author":"Anand","year":"1997","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0031-6997(25)06718-3","article-title":"Low molecular weight heparin: a critical analysis of clinical trials","volume":"46","author":"Green","year":"1994","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1378\/chest.11-2291_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.1983.123","article-title":"Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin","volume":"34","author":"Whitfield","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1378\/chest.11-2291_bib90","first-page":"463","article-title":"Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants","volume":"70","author":"Edson","year":"1967","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib91","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0002-8703(05)80172-3","article-title":"Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality","volume":"119","author":"Becker","year":"1990","journal-title":"Am Heart J"},{"issue":"8829","key":"10.1378\/chest.11-2291_bib92","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/0140-6736(92)92935-9","article-title":"Heparin resistance after aprotinin","volume":"340","author":"Fisher","year":"1992","journal-title":"Lancet"},{"issue":"9","key":"10.1378\/chest.11-2291_bib93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7326\/0003-4819-115-9-727","article-title":"Stroke prevention in nonvalvular atrial fibrillation","volume":"115","author":"Albers","year":"1991","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1378\/chest.11-2291_bib94","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin","volume":"359","author":"Blossom","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.11-2291_bib95","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bcp.2009.04.012","article-title":"Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins","volume":"78","author":"Li","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib96","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1592\/phco.21.1.108.34436","article-title":"Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity","volume":"21","author":"Carlson","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1378\/chest.11-2291_bib97","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"30","key":"10.1378\/chest.11-2291_bib98","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.1074\/jbc.M600169200","article-title":"Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway","volume":"281","author":"Rajgopal","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.11-2291_bib99","series-title":"Protamine Sulfate: Antiheparin Agents","author":"American Society of Heath-system Pharmacists","year":"1999"},{"issue":"3","key":"10.1378\/chest.11-2291_bib100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM197607152950318","article-title":"Letter: Protamine sulfate and fish allergy","volume":"295","author":"Caplan","year":"1976","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib101","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0003-4975(10)64597-3","article-title":"Reoperations for valve surgery: perioperative mortality and determinants of risk for 1,000 patients, 1958-1984","volume":"42","author":"Lytle","year":"1986","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1378\/chest.11-2291_bib102","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/0310057X9902700314","article-title":"Recent experiences with hexadimethrine for neutralizing heparin after cardiopulmonary bypass","volume":"27","author":"Cooney","year":"1999","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"10.1378\/chest.11-2291_bib103","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1213\/00000539-199608000-00004","article-title":"Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass","volume":"83","author":"Kikura","year":"1996","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1378\/chest.11-2291_bib104","first-page":"670","article-title":"In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients","volume":"79","author":"Despotis","year":"1994","journal-title":"Anesth Analg"},{"issue":"suppl 1","key":"10.1378\/chest.11-2291_bib105","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/00005344-199600001-00012","article-title":"Restoration of the normal coagulation process: advances in therapies to antagonize heparin","volume":"27","author":"D'Ambra","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"10.1378\/chest.11-2291_bib106","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/01.CIR.91.8.2188","article-title":"Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans","volume":"91","author":"Dehmer","year":"1995","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.11-2291_bib107","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00003246-199806000-00035","article-title":"Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device\u2014an alternative to protamine","volume":"26","author":"Tao","year":"1998","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib108","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0741-5214(97)70018-1","article-title":"A novel protamine variant reversal of heparin anticoagulation in human blood in vitro","volume":"26","author":"Hulin","year":"1997","journal-title":"J Vasc Surg"},{"issue":"2","key":"10.1378\/chest.11-2291_bib109","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/bj1930395","article-title":"The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin","volume":"193","author":"Holmer","year":"1981","journal-title":"Biochem J"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib110","first-page":"1","article-title":"Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties","volume":"16","author":"Holmer","year":"1986","journal-title":"Haemostasis"},{"issue":"21","key":"10.1378\/chest.11-2291_bib111","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/S0021-9258(19)70431-1","article-title":"The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin","volume":"255","author":"Jordan","year":"1980","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1378\/chest.11-2291_bib112","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0049-3848(85)90202-6","article-title":"The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis","volume":"38","author":"Bergqvist","year":"1985","journal-title":"Thromb Res"},{"issue":"6","key":"10.1378\/chest.11-2291_bib113","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V59.6.1239.1239","article-title":"The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits","volume":"59","author":"Carter","year":"1982","journal-title":"Blood"},{"issue":"4","key":"10.1378\/chest.11-2291_bib114","first-page":"CD001100","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","volume":"18","author":"van Dongen","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1378\/chest.11-2291_bib115","first-page":"65","article-title":"Pharmacokinetics of low molecular weight heparins","volume":"543","author":"Bara","year":"1988","journal-title":"Acta Chir Scand Suppl"},{"issue":"6","key":"10.1378\/chest.11-2291_bib116","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.1987.tb03100.x","article-title":"ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man","volume":"23","author":"Bradbrook","year":"1987","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1378\/chest.11-2291_bib117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0049-3848(86)90340-3","article-title":"Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers","volume":"42","author":"Bratt","year":"1986","journal-title":"Thromb Res"},{"issue":"3","key":"10.1378\/chest.11-2291_bib118","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0038-1646593","article-title":"Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit","volume":"61","author":"Briant","year":"1989","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1378\/chest.11-2291_bib119","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0038-1651070","article-title":"Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers","volume":"57","author":"M\u00e4tzsch","year":"1987","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1378\/chest.11-2291_bib121","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1378\/chest.11-2291_bib122","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.7326\/0003-4819-119-11-199312010-00008","article-title":"Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty","volume":"119","author":"Anderson","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib123","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archinte.159.1.46","article-title":"A randomized trial comparing 5-mg and 10-mg warfarin loading doses","volume":"159","author":"Crowther","year":"1999","journal-title":"Arch Intern Med"},{"issue":"20","key":"10.1378\/chest.11-2291_bib124","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.11-2291_bib125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","article-title":"Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity","volume":"116","author":"Choay","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1378\/chest.11-2291_bib126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00280041","article-title":"Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin","volume":"39","author":"Handeland","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1002751","article-title":"Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit","volume":"14","author":"Boneu","year":"1988","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.11-2291_bib128","first-page":"129","article-title":"Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance","volume":"40","author":"Palm","year":"1985","journal-title":"Thromb Res"},{"issue":"5B","key":"10.1378\/chest.11-2291_bib129","doi-asserted-by":"crossref","first-page":"33L","DOI":"10.1016\/S0002-9149(98)00111-8","article-title":"Monitoring of low-molecular-weight heparins in cardiovascular disease","volume":"82","author":"Abbate","year":"1998","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1378\/chest.11-2291_bib130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2106\/00004623-199709000-00011","article-title":"Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin","volume":"79","author":"Francis","year":"1997","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"10.1378\/chest.11-2291_bib131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-2712(18)30347-0","article-title":"Contemporary laboratory monitoring of low molecular weight heparins","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"issue":"9","key":"10.1378\/chest.11-2291_bib132","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib133","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"4\u20135","key":"10.1378\/chest.11-2291_bib134","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0049-3848(92)90213-T","article-title":"Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in postsurgical patients treated with either Logiparin or unfractionated heparin","volume":"65","author":"Bara","year":"1992","journal-title":"Thromb Res"},{"issue":"8791","key":"10.1378\/chest.11-2291_bib135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"key":"10.1378\/chest.11-2291_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0049-3848(91)90403-J","article-title":"Laboratory monitoring of the clinical effects of low molecular weight heparins","volume":"14","author":"Walenga","year":"1991","journal-title":"Thromb Res"},{"issue":"6","key":"10.1378\/chest.11-2291_bib137","first-page":"698","article-title":"Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis","volume":"71","author":"Alhenc-Gelas","year":"1994","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1378\/chest.11-2291_bib138","first-page":"799","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban","volume":"122","author":"Laposata","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1378\/chest.11-2291_bib139","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0038-1648866","article-title":"Low molecular weight heparin therapy: is monitoring needed?","volume":"72","author":"Boneu","year":"1994","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2291_bib140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1378\/chest.11-2291_bib141","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","article-title":"Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes","volume":"143","author":"Becker","year":"2002","journal-title":"Am Heart J"},{"issue":"25","key":"10.1378\/chest.11-2291_bib142","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib143","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"issue":"5","key":"10.1378\/chest.11-2291_bib144","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1378\/chest.11-2291_bib145","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archinte.165.3.258","article-title":"Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis","volume":"165","author":"de Denus","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1378\/chest.11-2291_bib146","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bjs.4068","article-title":"Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients","volume":"90","author":"Frederiksen","year":"2003","journal-title":"Br J Surg"},{"issue":"4\u20135","key":"10.1378\/chest.11-2291_bib147","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0049-3848(02)00188-3","article-title":"Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis","volume":"106","author":"Heizmann","year":"2002","journal-title":"Thromb Res"},{"issue":"15","key":"10.1378\/chest.11-2291_bib148","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger","year":"2008","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib149","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1381\/09608920160558588","article-title":"Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial","volume":"11","author":"Kalfarentzos","year":"2001","journal-title":"Obes Surg"},{"issue":"1","key":"10.1378\/chest.11-2291_bib150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1381\/096089202321144522","article-title":"A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery","volume":"12","author":"Scholten","year":"2002","journal-title":"Obes Surg"},{"issue":"6","key":"10.1378\/chest.11-2291_bib151","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.thromres.2009.04.021","article-title":"Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study)","volume":"124","author":"Imberti","year":"2009","journal-title":"Thromb Res"},{"issue":"11","key":"10.1378\/chest.11-2291_bib152","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00464-008-9997-6","article-title":"Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery","volume":"22","author":"Simone","year":"2008","journal-title":"Surg Endosc"},{"issue":"2","key":"10.1378\/chest.11-2291_bib153","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1592\/phco.21.2.169.34113","article-title":"The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease","volume":"21","author":"Brophy","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1378\/chest.11-2291_bib154","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000186641","article-title":"Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure","volume":"59","author":"Goudable","year":"1991","journal-title":"Nephron"},{"issue":"6","key":"10.1378\/chest.11-2291_bib155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270003253420","article-title":"Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin","volume":"43","author":"Chow","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1378\/chest.11-2291_bib156","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink","year":"2002","journal-title":"Thromb Res"},{"issue":"10","key":"10.1378\/chest.11-2291_bib157","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1538-7836.2009.03556.x","article-title":"Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency","volume":"7","author":"Schmid","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1378\/chest.11-2291_bib158","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","article-title":"Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)","volume":"79","author":"Mismetti","year":"1998","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2291_bib159","first-page":"800","article-title":"Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1378\/chest.11-2291_bib160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2291_bib161","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am Heart J"},{"issue":"3","key":"10.1378\/chest.11-2291_bib162","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200326030-00005","article-title":"Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients","volume":"26","author":"Cestac","year":"2003","journal-title":"Drug Saf"},{"issue":"7","key":"10.1378\/chest.11-2291_bib163","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.20.9.771.35210","article-title":"Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency","volume":"20","author":"Gerlach","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1378\/chest.11-2291_bib164","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"Sanderink","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1378\/chest.11-2291_bib165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcrc.2005.09.009","article-title":"Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency","volume":"20","author":"Rabbat","year":"2005","journal-title":"J Crit Care"},{"issue":"16","key":"10.1378\/chest.11-2291_bib166","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/archinte.168.16.1805","article-title":"Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study","volume":"168","author":"Douketis","year":"2008","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1378\/chest.11-2291_bib167","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2291_bib168","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-3848(87)90343-4","article-title":"Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors","volume":"48","author":"Lindblad","year":"1987","journal-title":"Thromb Res"},{"issue":"2","key":"10.1378\/chest.11-2291_bib169","first-page":"139","article-title":"Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation","volume":"16","author":"Massonnet-Castel","year":"1986","journal-title":"Haemostasis"},{"issue":"2","key":"10.1378\/chest.11-2291_bib170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-2007-1004373","article-title":"Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments","volume":"11","author":"Racanelli","year":"1985","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1378\/chest.11-2291_bib171","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0038-1653794","article-title":"Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man","volume":"73","author":"Wolzt","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2291_bib172","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH07-05-0357","article-title":"Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro","volume":"100","author":"Gatt","year":"2008","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2291_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V79.1.1.1","article-title":"Low molecular weight heparin","volume":"79","author":"Hirsh","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1378\/chest.11-2291_bib174","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1378\/chest.11-2291_bib175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0038-1645207","article-title":"Neutralization of enoxaparine-induced bleeding by protamine sulfate","volume":"63","author":"Van Ryn-McKenna","year":"1990","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1378\/chest.11-2291_bib176","first-page":"155","article-title":"Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate","volume":"21","author":"Bang","year":"1991","journal-title":"Haemostasis"},{"issue":"4","key":"10.1378\/chest.11-2291_bib177","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-003-0633-1","article-title":"Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin","volume":"82","author":"Ng","year":"2003","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1378\/chest.11-2291_bib178","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0049-3848(98)00201-1","article-title":"Low molecular weight protamine: a potential nontoxic heparin antagonist","volume":"94","author":"Byun","year":"1999","journal-title":"Thromb Res"},{"issue":"5","key":"10.1378\/chest.11-2291_bib179","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0741-5214(05)80016-3","article-title":"Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine","volume":"21","author":"Wakefield","year":"1995","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1378\/chest.11-2291_bib180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1006\/jsre.1996.0261","article-title":"A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation","volume":"63","author":"Wakefield","year":"1996","journal-title":"J Surg Res"},{"issue":"suppl 3","key":"10.1378\/chest.11-2291_bib181","first-page":"43","article-title":"Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine","volume":"25","author":"Dietrich","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib182","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1076029610366439","article-title":"In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative","volume":"16","author":"Kuziej","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib183","first-page":"204","article-title":"Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin","volume":"20","author":"Monreal","year":"1990","journal-title":"Haemostasis"},{"issue":"3","key":"10.1378\/chest.11-2291_bib184","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0038-1645074","article-title":"Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats","volume":"63","author":"M\u00e4tzsch","year":"1990","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1378\/chest.11-2291_bib185","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood.V89.9.3236","article-title":"A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats","volume":"89","author":"Muir","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1378\/chest.11-2291_bib186","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107602960200800309","article-title":"Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation","volume":"8","author":"Kock","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib187","first-page":"451","article-title":"Effects of enoxaparin on histomorphometric parameters of bones in rats","volume":"56","author":"Folwarczna","year":"2004","journal-title":"Pol J Pharmacol"},{"issue":"2","key":"10.1378\/chest.11-2291_bib188","first-page":"122","article-title":"Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium","volume":"9","author":"Casele","year":"2000","journal-title":"J Matern Fetal Med"},{"issue":"2","key":"10.1378\/chest.11-2291_bib189","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","article-title":"Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin","volume":"87","author":"Pettil\u00e4","year":"2002","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2291_bib190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000073848","article-title":"Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism","volume":"33","author":"Wawrzysnka","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"1","key":"10.1378\/chest.11-2291_bib191","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0961203309353171","article-title":"Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?","volume":"19","author":"Lefkou","year":"2010","journal-title":"Lupus"},{"key":"10.1378\/chest.11-2291_bib192","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1749-6632.1981.tb29770.x","article-title":"Structural studies on a biologically active hexasaccharide obtained from heparin","volume":"370","author":"Choay","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1378\/chest.11-2291_bib193","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0008-6215(00)81050-2","article-title":"Further characterization of the antithrombin-binding sequence in heparin","volume":"100","author":"Thunberg","year":"1982","journal-title":"Carbohydr Res"},{"issue":"2","key":"10.1378\/chest.11-2291_bib194","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004362","article-title":"Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments","volume":"11","author":"Choay","year":"1985","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"10.1378\/chest.11-2291_bib195","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1021\/bi00394a024","article-title":"Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III","volume":"26","author":"Atha","year":"1987","journal-title":"Biochemistry"},{"issue":"6","key":"10.1378\/chest.11-2291_bib196","first-page":"1122","article-title":"Anti-Xa monitoring: inter-assay variability","volume":"84","author":"Depasse","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib197","first-page":"1289","article-title":"Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability","volume":"82","author":"Kitchen","year":"1999","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1378\/chest.11-2291_bib198","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003088-200241002-00003","article-title":"Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs","volume":"41","author":"Lieu","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib201","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","article-title":"Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins","volume":"41","author":"Paolucci","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"10.1378\/chest.11-2291_bib202","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1378\/chest.11-2291_bib203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2004-05-2010","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin","volume":"105","author":"Savi","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1378\/chest.11-2291_bib204","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"issue":"25","key":"10.1378\/chest.11-2291_bib205","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1378\/chest.11-2291_bib206","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1378\/chest.11-2291_bib207","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10245330500093492","article-title":"Fondaparinux: a potential new therapy for HIT","volume":"10","author":"Kuo","year":"2005","journal-title":"Hematology"},{"issue":"10","key":"10.1378\/chest.11-2291_bib208","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1345\/aph.1M136","article-title":"Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues","volume":"43","author":"Blackmer","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1378\/chest.11-2291_bib209","first-page":"ECR32","article-title":"Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins","volume":"88","author":"Parody","year":"2003","journal-title":"Haematologica"},{"issue":"4","key":"10.1378\/chest.11-2291_bib210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-002-2091-5","article-title":"Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts","volume":"73","author":"Matziolis","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1378\/chest.11-2291_bib211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bjs.4809","article-title":"Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro","volume":"92","author":"Handschin","year":"2005","journal-title":"Br J Surg"},{"issue":"5","key":"10.1378\/chest.11-2291_bib212","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1055\/s-0037-1613092","article-title":"Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro","volume":"87","author":"Lagrange","year":"2002","journal-title":"Thromb Haemost"},{"issue":"18","key":"10.1378\/chest.11-2291_bib213","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1056\/NEJM200404293501825","article-title":"Minor transplacental passage of fondaparinux in vivo","volume":"350","author":"Dempfle","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.11-2291_bib214","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00019501-199606000-00004","article-title":"Biochemistry and biology of hirudin","volume":"7","author":"Toschi","year":"1996","journal-title":"Coron Artery Dis"},{"issue":"2","key":"10.1378\/chest.11-2291_bib215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-999007","article-title":"Hirudins: from leeches to man","volume":"22","author":"Wallis","year":"1996","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1378\/chest.11-2291_bib216","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0009-9236(97)90151-X","article-title":"Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin","volume":"62","author":"Lef\u00e8vre","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1378\/chest.11-2291_bib217","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2006-02-001057","article-title":"Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin","volume":"108","author":"Tardy","year":"2006","journal-title":"Blood"},{"issue":"30","key":"10.1378\/chest.11-2291_bib218","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"issue":"4","key":"10.1378\/chest.11-2291_bib219","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0022-2836(91)90939-4","article-title":"Structure of the hirugen and hirulog 1 complexes of alpha-thrombin","volume":"221","author":"Skrzypczak-Jankun","year":"1991","journal-title":"J Mol Biol"},{"issue":"pt 2","key":"10.1378\/chest.11-2291_bib220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1042\/bj2870663","article-title":"Hirulog-1 and -B2 thrombin specificity","volume":"287","author":"Witting","year":"1992","journal-title":"Biochem J"},{"issue":"2","key":"10.1378\/chest.11-2291_bib221","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"issue":"suppl F","key":"10.1378\/chest.11-2291_bib222","first-page":"33F","article-title":"The use of bivalirudin in patients with renal impairment","volume":"12","author":"Robson","year":"2000","journal-title":"J Invasive Cardiol"},{"issue":"5","key":"10.1378\/chest.11-2291_bib223","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/17425250902845646","article-title":"Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome","volume":"5","author":"White","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1378\/chest.11-2291_bib224","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4899-2418-6_3","article-title":"Inhibitor binding to thrombin: x-ray crystallographic studies","volume":"340","author":"Banner","year":"1993","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1378\/chest.11-2291_bib225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-2007-996128","article-title":"Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor","volume":"23","author":"Hursting","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1378\/chest.11-2291_bib226","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1378\/chest.11-2291_bib227","first-page":"958","article-title":"Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation","volume":"94","author":"Warkentin","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2291_bib228","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1592\/phco.25.2.157.56950","article-title":"Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin","volume":"25","author":"Arpino","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"suppl 2","key":"10.1378\/chest.11-2291_bib229","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1378\/chest.127.2_suppl.27S","article-title":"Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia","volume":"127","author":"Bartholomew","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1378\/chest.11-2291_bib230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/107602960501100306","article-title":"Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia","volume":"11","author":"Hursting","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1378\/chest.11-2291_bib231","first-page":"446","article-title":"A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate","volume":"96","author":"S\u00f8rensen","year":"2006","journal-title":"Thromb Haemost"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:28:46Z","timestamp":1757917726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369212601184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":231,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0012369212601184"],"URL":"https:\/\/doi.org\/10.1378\/chest.11-2291","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parenteral Anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.11-2291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}